TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02845635

Intervention type: OTHER
Intervention: Personal history of multiple sclerosis
Description: Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.

Intervention type: OTHER
Intervention: Personal history of multiple sclerosis
Description: Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.

Intervention type: OTHER
Intervention: Personal history of multiple sclerosis
Description: Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.

Intervention type: OTHER
Intervention: Personal history of multiple sclerosis
Description: Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.
Study: NCT03398655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-111 + Paclitaxel
Description: VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Paclitaxel
Description: Placebo will be administered intravenously every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
Study: NCT04168047

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Barostat procedure
Description: Pressure threshold will be measured during the barostat procedure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Barostat procedure
Description: Pressure threshold will be measured during the barostat procedure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Barostat procedure
Description: Pressure threshold will be measured during the barostat procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Barostat procedure
Description: Pressure threshold will be measured during the barostat procedure

Intervention type: OTHER
Group type: OTHER
Intervention: Anxiety and Depression Evaluation
Description: Anxiety and Depression will be measured using HAD anxiety and depression scale

Intervention type: OTHER
Group type: OTHER
Intervention: Anxiety and Depression Evaluation
Description: Anxiety and Depression will be measured using HAD anxiety and depression scale

Intervention type: OTHER
Group type: OTHER
Intervention: Anxiety and Depression Evaluation
Description: Anxiety and Depression will be measured using HAD anxiety and depression scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety and Depression Evaluation
Description: Anxiety and Depression will be measured using HAD anxiety and depression scale

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of sleep quality
Description: Sleep quality will be measured using Pittsburg sleep quality index

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of sleep quality
Description: Sleep quality will be measured using Pittsburg sleep quality index

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of sleep quality
Description: Sleep quality will be measured using Pittsburg sleep quality index

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of sleep quality
Description: Sleep quality will be measured using Pittsburg sleep quality index
Study: NCT00969059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553
Description: GW856553 is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered 7.5mg bid, orally with food at breakfast and dinner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Matching Placebo is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered orally with food at breakfast and dinner.
Study: NCT04496882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemlidy
Description: 25mg Tenofovir Alafenamide
Study: NCT01776619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: 14 day repeated 20mg BID doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 14 day repeated BID doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: 14 day repeated 80mg BID doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 14 day repeated BID doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: 14 day repeated 40mg BID doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 14 day repeated BID doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: 14 day repeated BID doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: relative bioavailability tablet vs. solution and food effect at 50mg dose
Study: NCT01001676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Description: Angioplasty with the use of Conventional balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Eluting Balloon Angioplasty
Description: Angioplasty with the use of paclitaxel eluting balloon
Study: NCT02393079

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A SHAM identical helmet will be used in the control group.
Study: NCT02369029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 1238097
Description: Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
Study: NCT01038908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isosulfan Blue (Patent Blue Dye V)
Description: 1. Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~2. Pre-incision: SLN is identified~3. Inject blue dye into patient's arm~4. Complete procedure (SLNB and/or ALND)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isosulfan Blue (Patent Blue Dye V)
Description: 1. Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~2. Pre-incision: SLN is not identified (No localization)~3. Inject blue dye into breast (nothing in arm)~i. No localization: Inject blue dye into arm and perform ALND ii. Localization: Complete procedure (SLNB and/or ALND)
Study: NCT03140436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate powders with grain size 65 µm
Description: sodium bicarbonate powders with grain size 65 µm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate powders with grain size 40 µm
Description: sodium bicarbonate powders with grain size 40 µm
Study: NCT03538626

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB091-00-AB
Description: N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB091-00-AB
Description: N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB091-00-AB
Description: N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB091-00-AB
Description: N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB091-00-AB
Description: N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB091-00-AB
Description: N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB091-00-AB
Description: N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB091-00-AB
Description: N6LS (VRC-HIVMAB091-00-AB) is a human monoclonal antibody targeted to the HIV-1 CD4 binding site.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Recombinant human hyaluronidase PH20 (rHuPH20) is the active ingredient of the investigational ENHANZE™ Drug Product (EDP). EDP is a purified preparation of rHuPH20.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Recombinant human hyaluronidase PH20 (rHuPH20) is the active ingredient of the investigational ENHANZE™ Drug Product (EDP). EDP is a purified preparation of rHuPH20.
Study: NCT01434602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation: 5mg to 10mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation: 5mg to 10mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Patients will be treated with sorafenib in combination with everolimus (days 1-28); There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation 400mg-600mg twice a day (bid) or 400mg-800mg twice a day, 7 days on and 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Patients will be treated with sorafenib in combination with everolimus (days 1-28); There is not a defined set maximum number of cycles that a patient may have; Phase I Dose Escalation 400mg-600mg twice a day (bid) or 400mg-800mg twice a day, 7 days on and 7 days off.
Study: NCT04239313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)
Description: Population I are coxal muscle injection of low dose vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)
Description: Population I are coxal muscle injection of low dose adjuvant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo
Description: The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I are coxal muscle injection of placebo.
Study: NCT02025023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Curettage
Description: If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide/5-fluorouracil mixture
Description: If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.
Study: NCT03367845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Parents receive 8 phone contacts (1 per week) that do not focus on material in the sensitivity and couples communication intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensitivity Intervention
Description: 4 home visits take place. Mothers and fathers are video recorded with their infant (separately) for approximate 10-15 minutes at the beginning of each visit. The recorded situations are natural (e.g., playing together, bathing the baby, mealtime, etc.) and the family coach (interventionist) is not actively involved in the parent-child interaction. A different theme is covered across the four intervention sessions. For each parent-infant interaction recording, the family coach reviews the recordings between visits and provides feedback to parents in the following intervention session. The exception to this is that video of parent-child interactions during the lab pre-test is used for material at the first home visit. Each session takes approximately 90 minutes. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples' Intervention
Description: The psycho-educational inter-parental conflict prevention curriculum is a 4-session program that takes place in the families' homes. Each session lasts approximately 90 minutes and involves discussion and practice of four themes pertinent to improving conflict process, communication, and emotional security in the family: Conflict Overview, Interparental Conflict and Children, Stresses of Parenting, and Emotional Security. The family coach scaffolds and supports the couples' development of constructive conflict behaviors. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensitivity and Couples' Intervention
Description: This group receives both the Sensitivity and Couples' Intervention in their home. There are 8 home visits (4 for Sensitivity and 4 for Couples Intervention). Because of COVID-19, we now conduct remote visits using Zoom.
Study: NCT00828568

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Imiquimod Vehicle manufactured by Taro
Description: Treatment applied as a thin layer to target area once daily, 2 days each week, for 16 weeks
Study: NCT03150719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor/Ivacaftor
Description: TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
Study: NCT01463566

Intervention type: DEVICE
Intervention: Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System
Description: Gender Solutions Natural Knee Flex System in total knee arthroplasty
Study: NCT01241565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDO GIA™ Stapler with TRI-STAPLE™ Technology
Description: All patients will have surgery with ENDO GIA™ Stapler with TRI-STAPLE™ Technology
Study: NCT03386149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosinji
Description: Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~* Rehmannia Root 1.7g~* Achyranthes Root 1.0g~* Cornus Fruit 1.0g~* Dioscorea Rhizome 1.0g~* Psyllium Husk 1.0g~* Alisma Rhizome 1.0g~* Hoelen 1.0g~* Moutan Root Bark 1.0g~* Cinnamon Bark 0.3g~* Pulvis Aconiti Tuberis Purificatum 0.3g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxonine tab.
Description: Product name : Loxonine tab. Manufacturer : Dong Wha Pharm. Co., Ltd Ingredient : Loxoprofen Sodium 68.1mg (Loxoprofen 60mg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture treatment will be performed on 20 predefined acupoint using 0.25mm x 40mm acupuncture needle. The time for needle retaining is 15 minutes.~1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints)~2. Both side BL24, BL25, BL26, EX-B7, BL28 (10 acupoints)~3. Symptomatic side GB30, GB34, BL57, ST36 (4 acupoints)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatment will be performed on 20 predefined acupoint using 0.25mm x 40mm acupuncture needle. The time for needle retaining is 15 minutes.~1. Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints)~2. Both side BL24, BL25, BL26, EX-B7, BL28 (10 acupoints)~3. Symptomatic side GB30, GB34, BL57, ST36 (4 acupoints)
Study: NCT00783978

Intervention type: OTHER
Intervention: whole blood sample
Description: 2 ml of whole blood for children 5 ml of whole blood for parents that will be used only if 1 mutation is found in children
Study: NCT03150719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: IVA 150 mg tablet.
Study: NCT00644605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
Study: NCT02561013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Coban™ Custom Fit Compression System
Description: 3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve.~The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Profore
Description: PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.
Study: NCT03150719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to TEZ/IVA fixed-dose combination tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to IVA tablet.
Study: NCT02248285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FilmArray™ Gastrointestinal (GI) Panel
Description: BioFire Diagnostics, LLC (BioFire) has developed a polymerase chain reaction (PCR), high-resolution melting analysis instrument called the FilmArray™ and an associated reagent pouch that together are capable of simultaneously detecting multiple microorganisms in a single sample. The FilmArray™ Gastrointestinal (GI) Panel pouch contains freeze-dried reagents to perform nucleic acid purification and nested, multiplex PCR for the identification of common bacterial, viral, and parasite microorganisms responsible for infectious gastroenteritis. The test was made available for sale in the US and EU following FDA clearance and CE marking in May, 2014
Study: NCT03767673

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Initial Spirometry
Description: Determination of Vital Capacity by spirometry before (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
Study: NCT00466245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVA Smallpox vaccine
Description: Two 0.5mL subcutaneous injections, separated by 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVA Smallpox vaccine
Description: Two 0.5mL subcutaneous injections, separated by 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVA Smallpox vaccine
Description: Two 0.5mL subcutaneous injections, separated by 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVA Smallpox vaccine
Description: Two 0.5mL subcutaneous injections, separated by 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVA Smallpox vaccine
Description: Two 0.5mL subcutaneous injections, separated by 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVA Smallpox vaccine
Description: Two 0.5mL subcutaneous injections, separated by 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two 0.5mL subcutaneous injections, separated by 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two 0.5mL subcutaneous injections, separated by 28 days
Study: NCT00758290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Fluoride
Description: Brush twice daily for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride/triclosan
Description: Brush daily for 3 weeks
Study: NCT04553601

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT and PET/CT-guide targeted biopsy in another group of participants
Description: Each subject receive a single intravenous injection of 18F-FDG PET/CT and PET/CT-guide targeted biopsy within the specified time
Study: NCT01367886

Intervention type: DRUG
Group type: OTHER
Intervention: fesoterodine
Description: Fesoterodine 4 mg. tablet by mouth daily for six weeks
Study: NCT01862926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study: NCT03767673

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial Spirometry
Description: Determination of Vital Capacity by spirometry before (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
Study: NCT01108081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Moderate-intensity physical activity
Study: NCT02278445

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Recording Doppler ultrasound noninvasively from the right chest wall

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)
Study: NCT01823328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Subjects will receive ketamine for sedation prior to rapid sequence intubation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Subjects will receive etomidate for sedation prior to rapid sequence intubation.